Becky M Bautch, AGACNP-BC Registered Nurse Medicare: Medicare Enrolled Practice Location: 90 Hope Dr Bldg 6000, Mountain Home Afb, ID 83648 Phone: 208-828-7900 |
Lydia Rodriguez, WHNP Registered Nurse - Obstetric, Inpatient Medicare: Not Enrolled in Medicare Practice Location: 90 Hope Dr Bldg 6000, Mountain Home Afb, ID 83648 Phone: 208-828-7111 |
Miss Leigh Anne Palmer, Registered Nurse - Medical-Surgical Medicare: Not Enrolled in Medicare Practice Location: 90 Hope Dr Bldg 6000, Mountain Home Afb, ID 83648 Phone: 208-828-7170 |
News Archive
Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.
Despite the enormous unmet need for treatment of substance use disorders and the promise of telemedicine to fill some of the gaps in care, the tool remains woefully underused, according to research led by investigators from the Blavatnik Institute at Harvard Medical School.
Today the U.S. Food and Drug Administration (FDA) released two separate draft guidance documents to help fight the tobacco epidemic and stop children from using tobacco. The draft guidance documents implement provisions of the Family Smoking Prevention and Tobacco Control Act that will ultimately provide the public with previously unknown information about the chemicals in tobacco products and help prevent misleading marketing about the risks associated with tobacco products.
The University of Tokyo entered an agreement for developing a personalized cancer vaccine using a novel method involving the body's immune response.
› Verified 5 days ago